Amnis developed the ImageStream and FlowSight imaging flow cytometry platforms. These systems simultaneously produce 12 high resolution images of each cell directly in fluid flow, at rates up to 5,000 cells per second, and with fluorescence sensitivity that exceeds traditional microscopy or flow cytometry. Amnis' imaging technology is protected by more than 50 issued US and international patents. The company was founded in 1999 by David Basiji and William Ortyn. Amnis was acquired in 2011 by EMD Millipore, a division of Merck KGaA now called MilliporeSigma, for $110 million. MilliporeSigma sold Amnis to Luminex Corporation in late 2018.